Navigation Links
Hospira Expands Board of Directors
Date:8/17/2011

LAKE FOREST, Ill., Aug. 17, 2011 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), a leading global specialty pharmaceutical and medication delivery company, today announced that William G. Dempsey has been elected to the company's board of directors. Dempsey brings strong executive management and diverse global experience from leadership positions held in the healthcare industry. The addition of Dempsey expands Hospira's board to 11 directors, nine of whom are independent.

(Logo:  http://photos.prnewswire.com/prnh/20040503/HSPLOGO)

"Bill understands how to successfully grow a large, multinational healthcare business," said Christopher B. Begley, executive chairman. "His impressive track record of results-oriented leadership and operational experience in the healthcare field makes him an excellent fit for the Hospira board."

John C. Staley, Hospira's lead director, added, "We are excited to welcome Bill to Hospira's board of directors. His broad and deep knowledge of global healthcare markets enhances our current board membership and supports Hospira's goals for international expansion."

Dempsey, 59, spent more than two decades at Abbott Laboratories, most recently serving as executive vice president, Global Pharmaceuticals, where he was responsible for the company's $14 billion global pharmaceutical business, representing more than 33,000 employees. In this position, from which he retired in 2007, he drove the business to 15 percent growth in revenues and profitability in the face of major new generic competition. He also led an initiative that doubled research and development productivity over three years, and negotiated and integrated the successful $3.7 billion acquisition of the cardiovascular company, Kos Pharmaceuticals.

From 2003 to 2006, Dempsey was Abbott's senior vice president, Pharmaceutical Operations, responsible for Abbott's $8 billion U.S. pharmaceuticals business. In this role, Dempsey consistently delivered strong sales growth and successfully launched the blockbuster rheumatoid arthritis drug Humira.

Previously, Dempsey was Abbott's senior vice president, International Operations, where he served from 1999 to 2003, managing all of Abbott's pharmaceutical, hospital and nutritional businesses outside the United States. During his tenure, he grew the business from approximately $3 billion in sales to $5 billion in sales.

In prior roles at Abbott, Dempsey served as senior vice president, Chemical and Agricultural Products, and vice president, Hospital Products Business Sector, among other positions. Before working at Abbott, Dempsey served in various roles at Sciaky Brothers Inc. and Crane Company.

Dempsey currently serves on the boards of Landauer, Inc. and Nordion, Inc. A native of Chicago, Ill., he holds a Bachelor of Science degree from DePaul University.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection
2. Hospira Reports Second-Quarter 2011 Results
3. Hospira to Host Conference Call for Second-Quarter 2011 Results
4. Hospira Receives Health Canada Regulatory Approval for Symbiq™ Infusion System Software Upgrade
5. Hospira to Present at the Sanford C. Bernstein Twenty-Seventh Annual Strategic Decisions Conference 2011
6. Hospira Highlights Progress in 2010 at Its 2011 Annual Meeting of Shareholders
7. Hospira Reports First-Quarter 2011 Results
8. Hospira Board Authorizes $1 Billion Share Repurchase Program
9. Hospira to Present at Bank of America / Merrill Lynch 2011 Health Care Conference May 11, 2011
10. Hospira Reinforces Importance of Clinical Surveillance Technology in Line With World Health Day Focus on Antimicrobial Resistance
11. Hospira to Host Conference Call for First-Quarter 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical Services, ... solutions for injectable drug administration, today shared the results ... Adapter for improving the intradermal administration of polio vaccines. ... Vaccination Summit in May 2017 by Dr. Ondrej ... Department, World Health Organization (WHO), and recently published in ...
(Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease ... end of October . PhysicianOne Urgent Care is helping communities across ... Westchester, NY , by offering no-cost* flu shots through the end ... mandated by certain health insurance regulations. ... The best time to get a flu shot is by the end ...
(Date:10/2/2017)...  AllianceRx Walgreens Prime, the combined central specialty pharmacy ... benefit manager Prime Therapeutics LLC (Prime), today officially began ... unveiling of new signage at its headquarters in ... a few other company-owned facilities across the country. This ... of whom will begin to see the AllianceRx Walgreens ...
Breaking Medicine Technology:
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 , ... ... of their peers in Washington, D.C., for the 49th Congress of the International ... Ph.D ., Vice President of the Center for Cancer and Blood Disorders ...
(Date:10/12/2017)... ... 12, 2017 , ... Health Literacy Innovations (HLI), creator of ... and the Cancer Patient Education Network (CPEN), an independent professional organization that shares ... strategic alliance. , As CPEN’s strategic partner, HLI will help support CPEN ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... ... Cal Dining at the University of California Berkeley, and other leading institutions in ... the buying power of institutions to change the way animals are raised for ...
Breaking Medicine News(10 mins):